Early-stage cancer screening biotech company New Horizon Health has raised as much as $20 million in a Series D funding round led by China-based healthcare-focused private equity firm Omniscient.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
